China / Boehringer Ingelheim's Stroke Rehab Centre Success & Continuing China Push
In March 2018, German pharma player Boehringer Ingelheim (BI)‘s Consanas Rehabilitation and the Shanghai…
Top Stories
France / Valneva: Small, but Poised for COVID-19 Vaccine Success
While Big Pharma companies like Pfizer, Janssen and AstraZeneca, have grabbed the headlines over the past year for their work on COVID-19 vaccines, smaller and lesser-known companies are also playing…
Singapore / Finding the Right Pharma Talent Post-COVID
Singapore – despite its modest USD 1.22 billion domestic market – has long been one of Asia’s leading…
Switzerland / A Sea Change in the Biotech Start-up Ecosystem?
In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine Venture Partners, a venture capital (VC)…
Russia / Biocad Ramps up Sputnik V Manufacturing; Unlicensed Remdesivir Generics; Chinese Vaccine Rejection
The latest news from Russian pharma, including Biocad’s ramping up of Sputnik V COVID-19 vaccine manufacturing,…
APAC / Novartis APAC Oncology Head & Singapore Country President Kevin Zou
Kevin Zou highlights Novartis Oncology’s footprint and priorities in the diverse Asia-Pacific region, the…
France / Top 10 Pharma Companies
The Top 10 pharma companies in the EUR 28.9 million French pharma market in 2019. Homegrown players Sanofi and…
In Conversation
Daniel Fung – CEO, Institute of Mental Health, Singapore
Singapore’s Institute of Mental Health offers a comprehensive range of psychiatric, rehabilitative, and psychotherapy services for the country’s population. CEO Associate Professor Daniel Fung discusses their work to transform mental illness treatments, why telemedicine will succeed, and how it plans to address population health by moving upstream to identify the at-risk and prevent illness. I see Singapore as a…
Latest Reports
Focus on China
Boehringer Ingelheim’s Stroke Rehab Centre Success…
In March 2018, German pharma player Boehringer Ingelheim (BI)'s Consanas…
New Drug Approvals in China 2020
The Chinese NMPA’s drug approval list for 2020 includes a surge in approvals…
China: AstraZeneca/Junshi anti-PD-1 Tie-Up; New UK Biologics…
The latest from Chinese pharma, including a new deal between AstraZeneca and…
China: Yangtze River Pharmaceutical Group (YRPG) in Profile
One of the largest domestic pharma companies in China (ranking number one from…
Read more: China >>
Focus on MEA
5 Things to Know about Saudi Arabian Pharma
A rundown of five things to know about the USD 8.2 billion Saudi pharma market,…
MEA: Pfizer’s Saudi Transformation; Urgent Call for Arab…
The latest news from Middle East & North African pharma, including…
MEA Roundup: Turkey’s Pharma Debt; Saudi Market Rise; UAE…
A roundup of the latest from the Middle East & Africa region, including…
MEA: Iran looks to Cuba for COVID-19 Vaccine; Israel Leads…
The latest COVID-19 vaccine news from the Middle East & Africa (MEA) region,…
Read more: MEA >>
Focus on Vaccines
Novavax: From No-Hoper to COVID-19 Vaccine Saviour?
From almost being de-listed by the NASDAQ stock index in 2018 due to poor…
Italy Pharma News: Mandatory COVID-19 Vaccines for…
The latest from Italian pharma, including the government’s decision to make…
LatAm Pharma News: COVAX Rollout in Colombia; União Quimica…
The latest LatAm pharma news, including COVID-19 vaccine rollouts in Colombia,…
Russia Pharma News: Biocad Ramps up Sputnik V Manufacturing;…
The latest news from Russian pharma, including Biocad’s ramping up of Sputnik…
Read more: Vaccines >>
Focus on Switzerland
Switzerland: A Sea Change in the Biotech Start-up Ecosystem?
In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine…
Swiss Pharma: Staying the Course
This article forms part of Healthcare & Life Sciences Review: Switzerland…
Swissmedic New Drug Approvals 2020
Regarded as one of the world’s leading regulatory bodies, Swissmedic stands…
Building a Health Data Ecosystem in Switzerland
Although Switzerland is ahead of many of its competitors in Europe on levels of…
Read more: Switzerland >>
Focus on Europe
Europe: EMA Medicine Approvals 2020
The full list of medicines recommended for approval by the European Medicines…
Can Europe’s Beating Cancer Plan Make it an Innovation…
The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating…
Switzerland: A Sea Change in the Biotech Start-up Ecosystem?
In a recent conversation with PharmaBoardroom, Michael Sidler of Redalpine…
Read more: Europe >>
Focus on Singapore
APAC: Prestige & HH&L IPO News; Cold Chain Vaccine…
The latest pharma news from the Asia-Pacific region, including upcoming IPOs for…
Singapore Pharma Industry Snapshot 2020
Singapore is home to a wide range of biopharmaceutical company headquarters,…
Medtech’s Post-COVID Paradigm in APAC
At USD 150 billion, Asia-Pacific is home to the world’s second largest medtech…
HSA: APAC’s Regulatory Gold Standard
As the most important pharma hub in its region, and one of the most important…
Read more: Singapore >>
Focus on USA
USA: 2 Things the Biden Administration can do Now to Lower…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can…
Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and…
5 US Rare Disease Start-Ups to Watch
Following on from our profile on five of the most promising clinical-stage…
NORD Chief Strategy Officer on Health Equity’s Vital…
With Rare Disease Day coming up on February 28th, one of the leading…